rais elagolix sale uf data
 creon sale sollpura result
elagolix uf dataset fda action endometriosi
catalyst
adj elagolix uterin fibroid uf probabl success met
efficaci endpoint trial elagolix low-dos hormon pt
respons vs control arm vs trial look
uf data snda file rais elagolix
sale uf market model assum penetr fda action
endometriosi en expect model global sale en/
uf rais creon sale
reiter pt ep support dcf
rais elagolix sale uf trial
expect click elagolix met primari rank secondari efficaci
endpoint second replic trial elari uterin fibroid
uf top-lin data abbv uf trial de-risk elagolix
highli preval lifetim incid uf pre-menopaus women
materi under-penetrated indic rais risk-adjust elagolix
sale year sale global
endometriosi uf market model vs street base
market model assum elagolix achiev us sale vs
street us estim see room upsid partner
neurocrin rate drive greater elagolix penetr increas
diagnosis/treat rate across endometriosi en uf market
maintain sales/ep vs street
rais vs street
higher elagolix creon sale follow anthera anth rate fail
sollpura trial final elagolix efficacy/safeti result
trial expect uf snda file assum near-term
elagolix catalyst includ fda action prioriti review elagolix
endometriosi click note reiter pt base
ep support dcf risk includ clinic regulatori
data delay risankizumab/upadacitinib lt data file
humira lower concentration/less burn formul launch us
well humira intellectu properti ip risk
tr target
elagolix hit us en/uf patient share
note click elagolix posit phase data endometriosi en uterin fibroid
uf indic high preval signific unmet medic need en lead
menstrual pain dysmenorrhea dy chronic non-menstru pelvic pain nmpp preval
women infertil accord scientif literatur diseas lead abnorm
growth endometri tissu affect women world-wide us approv
treatment option endometriosi includ analges gnrh agonist like abbv lupron
laparoscop surgeri challeng term efficaci safeti high invas
uterin fibroid uf lifetim incid pre-menopaus women us annual preval
uf associ earli pregnanc loss infertil approv treatment option uf
includ oral contracept pills/progestin gnrh agonist hysterectomi myomectomi
like en therapi challeng term low efficaci advers event invas
base market model less us patient endometriosi uterin
fibroid diagnos dx dx patient treat pharmacolog
therapi like lupron leuprolid astrazeneca azn rate zoladex goserelin other
instead dx patient treat surgic vast major either receiv
drug therapi receiv drug therapi manag symptom pain medic
think elagolix could meet signific unmet medic need two popul materi
under-diagnos undertr en uf market model estim elagolix potenti
us assum low-singl digit penetr rate diagnos en/uf market
assum us en uf diagnosi rate out-year increas modestli
penetr diagnos en popul repres sale penetr
dx uf popul equat well model elagolix sale
ex-u vs street us assum consensu us/ex-u
split elagolix market model assum global sale vs street
expect click announc elagolix met primari
rank secondari efficaci endpoint month six second replic phase trial
elari uterin fibroid uf result show six-month treatment elagolix
low-dos hormon therapi contribut clinic respons reduc heavi menstrual bleed
women vs placebo result line top-lin data
abbv first phase trial elari feb click show respons
patient vs placebo first pivot trial note hot flush reduct
bone miner densiti due elagolix treatment observ studi look forward
see full six-month elagolix data studi upcom medic meet american
societi reproduct medicin asrm oct denver evalu safeti profil
lack therapeut option en uf appear meet unmet medic need howev safeti
barrier commerci uptak elagolix efficacy/safeti result phase
trial expect support snda file uf
sollpura failur remov threat creon franchis
march anth rate announc result studi
sollpura liprotamas meet primari non-inferior endpoint exocrin pancreat
insuffici epi due cystic fibrosi anth suspend develop sollpura
remind sollpura design oral non-porcin pancreat enzym replac therapi
pert would compet directli abbv creon pancrelipas franchis creon post
sale us result remov near-term competit threat
rais creon estim modestli out-year model creon sale
vs street think sollpura failur also put upward pressur
our/street estim allergan buy zenpep anoth competitor pert space
model zenpep sale vs street
pipelin catalyst place upward pressur abbv multipl
bounti catalyst drive out-perform roll outth humira lower volume/
citrate-fre formul pediatr patient us mavyret launch trajectori trx/
sale figur import metric look build-out imbruvica label
includ interim result mantl cell lymphoma shine follicular lymphoma
selen expect venclexta r/r cll approv base data
page
expect upadacitinib data three rheumatoid arthriti trial select-
compar select-earli select-choic throughout aim submit nda
file upadacitinib base result six trial track submit psoriasi
result risankizumab fda support launch us catalyst
includ fda action elagolix endometriosi prioriti review rova-t top-lin data
triniti sclc
page
peak sale assum biosimilar entri
like weight base approv r/r cll
less
 sale
sg sale
impli us ex-u rang
tax rate rise next year rate lower due one-tim benefit
increas octob oper rest tax
page
exhibit estim strh vs consensu
page
exhibit pipelin strh vs consensu
page
page
anticip approv elagolix endometriosi prioriti review
sclc triniti data sclc
file base sclc triniti
file pso base result immvent immhanc
dlbcl possibl submiss dlbcl combo w/ rchop data phoenix
ra select-compar data
full data r/r fl vs br contralto
atop derm studi expect begin
full data dlbcl rchop vs rchop caval
initi evid biolog activ multipl sclerosi
regulatori file acut myeloid leukemia aml patient receiv high-dos induct thera
ema action expect adalimumab biosimilar file accept
uc studi expect begin
basket studi neuroendocrin tumor data avail
start see data rova-t combin opdivo/ yervoy
initi phase trial ulcer coliti
ra select-earli data
file upadacitinib
r/r fl/mzl combo w/ br r-chop selen
regulatori approv expect base r/r cll murano broader label cll
regulatori approv expect aml patient receiv high-dos induct therapi
rova-t launch expect sclc
page
ind novel target
nsclc start pivot nsclc monotherapi
file pso base result immvent immhanc
data phase trial multipl myeloma mm
three phase trial risankizumab crohn diseas
primari complet trial uterin fibroid
page
million
sale
sale
page
million
equival
defer tax receiv
net properti equip
account payabl accru liabil
current matur lt debt
page
accumul comprehens incom loss
total liabil equiti
exhibit statement flow
million
flow oper activ
depreci amort
chang asset liabil
net cash use oper activ
flow invest activ
purchas properti equip
acquisit invest net cash acquir
decreas increas restrict cash invest
decreas increas market secur net
net cash use invest activ
flow financ activ
proce repay short-term debt
proce issuanc long-term debt
repay long-term debt net
purchas common share
proce stock option exercis
net transact abbott laboratori
net cash flow provid financ activ
effect fx cash cash equival
net increas decreas cash cash equival
cash equival begin period
cash equival end period
page
inc highli focus research-driven biopharmaceut compani discov
develop deliv innov therapi treat health issu rang life-threaten ill
chronic condit gener total net sale sale deriv
us intern market compani core area expertis immunolog
hematology/oncolog virolog neurosci gener medicin
humira largest pharmaceut product histori biopharmaceut industri
total revenu come differ indic abbv second largest franchis hematology/
oncolog imbruvica/venclexta franchis account sale abbv
virolog franchis includ hepat product viekira/mavyret account
sale
rate buy one favorit valu name large-cap biopharmaceut
sinc launch believ time humira loss exclus us along
pipelin underappreci street thesi base humira us exclus
allow extract maximum valu franchis asset diversifi
revenu stream hematology/oncolog immunolog pipelin humira ideal
posit us volum driven growth price leverag well margin expans associ
expir upper single-digit royalti sale think evolv legal
regulatori landscap suggest us humira biosimilar competit delay januari
due long date humira patent estat global immunolog market model assum biosimilar
competit ex-u market late us earli legal catalyst around humira
play expect street push biosimilar entri us toward earli estim
put upward pressur street consensu humira sale estim
pipelin ideal posit view extern collabor intern
deriv asset provid next gener therapi autoimmun disord improv upon
humira best class profil posit leverag global humira infrastructur
pipelin immunolog asset includ upadacitinib select oral inhibitor risankizumab
monoclon antibodi target also posit reduc humira biosimilar risk
maxim hematology/oncolog franchis includ imbruvica venclexta hematolog
malign rova-t solid tumor model sales/ep cagr vs
street
valuat risk
price target assum trade ep premium major
biopharmaceut peer group expect abbv trade premium group settl
us patent disput humira pipelin matur multipl data read out immunolog
hematolog oncolog asset play model assum humira total sale account
sale immunolog hematology/oncolog sale new product
label expans exist asset rise sale
risk rate price target includ earlier expect humira biosimilar competit
us market addit assum compani abl gener revenu
pipelin lower humira total revenu clinic regulatori
commerci setback key pipelin asset upadacitinib risankizumab imbruvica venclexta rova-
elagolix etc could forc look extern acceler diversif sale prior
humira loss exclus us invest risk relat pharmaceut industri gener
includ continu price risk payer especi europ polit risk product develop
risk regulatori risk commerci risk legal risk patent challeng
compani mention note
inc anth rate
astrazeneca plc azn rate
inc rate
page
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
